What are the main financial results Amgen reported in this filing?

Amgen reported its unaudited financial results for the third quarter and the first nine months of 2020, along with its financial position as of September 30, 2020. The specific figures are detailed in the press release furnished as part of this 8-K filing.

Why is Amgen providing non-GAAP financial measures?

Amgen provides non-GAAP measures, such as non-GAAP earnings per share and net income, to offer investors a clearer perspective on the company's ongoing operational performance. These measures exclude certain expenses like acquisition-related charges and restructuring costs, which can be volatile and may not reflect the core business's profitability. The company believes this enhances the comparability of results across different periods.

What is Free Cash Flow (FCF) and why does Amgen report it?

Free Cash Flow (FCF) is a measure of liquidity calculated by subtracting capital expenditures from operating cash flow, both determined in accordance with GAAP. Amgen reports FCF to provide investors with an additional metric to assess the company's ability to generate cash from its operations after accounting for investments in its business.

What types of expenses are excluded from Amgen's non-GAAP financial measures?

Amgen excludes several types of expenses from its non-GAAP calculations. These primarily include acquisition-related expenses (such as amortization of acquired intangible assets), net charges related to restructuring initiatives, and other items deemed outside the ordinary course of business (like certain investment transaction adjustments and legal settlement impacts). These exclusions are intended to allow for a more meaningful evaluation of current operating performance.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on October 28, 2020, to report its unaudited financial results for the third quarter and the first nine months of 2020, as well as its financial position as of September 30, 2020. The filing includes a press release detailing these results and provides supplementary non-GAAP financial measures alongside standard GAAP figures. These non-GAAP measures, including non-GAAP earnings per share, operating income, and net income, are presented to offer investors a clearer view of ongoing operational performance by excluding items such as acquisition-related expenses, restructuring charges, and certain legal settlement impacts. The company also highlighted Free Cash Flow (FCF), a key liquidity metric, calculated as operating cash flow less capital expenditures. Amgen believes these non-GAAP adjustments provide a more meaningful comparison of its operational performance across different periods and facilitate a better understanding of the company's underlying business strength by treating acquired intellectual property similarly to internally developed assets. Investors should review the accompanying press release for detailed reconciliations between GAAP and non-GAAP figures.

Key Highlights

1Amgen reported its unaudited financial results for the three and nine months ended September 30, 2020.
2The company furnished a press release detailing these results, which is incorporated by reference.
3Amgen presented both GAAP and non-GAAP financial measures to provide a comprehensive view of its performance.
4Key non-GAAP measures include adjusted earnings per share, operating income, operating margin, tax rate, net income, and operating expenses.
5Free Cash Flow (FCF) was also reported as a measure of liquidity.
6Exclusions from non-GAAP measures include acquisition-related expenses (e.g., amortization of intangibles), restructuring initiative costs, and certain other non-ordinary course of business items.
7The company uses these non-GAAP measures to enhance comparability of ongoing business operations across periods.

AMGEN INC 8-K Report, Financial Results (Oct 28, 2020)

Summary

Key Highlights

Frequently Asked Questions